Myriad Genetics Inc. has announced the early access launch of its FirstGene Multiple Prenatal Screen through a large-scale clinical study. The screen aims to provide a comprehensive prenatal risk assessment for common genetic conditions with a single blood draw, eliminating the need for paternal testing. This initiative, part of the CONNECTOR study, will enroll over 5,000 patients across various clinical sites to evaluate the screen's effectiveness in real-world settings. The FirstGene screen has demonstrated more than 98.6% sensitivity and 99.6% specificity in previous tests. The study will generate clinical validity and utility evidence for the FirstGene screen as Myriad Genetics seeks to expand its prenatal portfolio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.